Visionary Breakthrough: FDA Approves Susvimo, a Revolutionary Shield Against Diabetic Blindness!
- Landmark FDA Approval: Genentech's Susvimo gains its third FDA nod, now for Diabetic Retinopathy (DR)1, 5, 6.
- Freedom from Frequent Injections: A pioneering implant offering continuous treatment with just one refill every nine months6, 7.
- New Hope for Millions: A game-changing option for nearly 10 million in the U.S. and over 100 million globally battling this sight-stealing condition6, 8.
In a monumental step forward in the war against vision loss, the U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab injection) for diabetic retinopathy. This isn't just another treatment; it's the first and only FDA-approved continuous delivery system proven to defend sight in DR patients, demanding only a single refill every nine remarkable months. For those who have previously responded to at least two anti-VEGF injections, Susvimo is now available, offering a new era of hope6, 8.
Diabetic retinopathy, a terrifying consequence of diabetes, casts a shadow over millions, threatening to steal their sight. But Susvimo, utilizing the innovative Port Delivery Platform (PDP)5, 6, delivers ranibizumab—a potent VEGF inhibitor—directly and consistently into the eye via a surgically inserted, refillable implant. This landmark approval follows Susvimo's prior successes in treating wet AMD (October 2021)3, 4 and diabetic macular edema (February 2025)2, 3, solidifying its role as a transformative force in eye care.
"The approval of Susvimo for diabetic retinopathy expands treatment options for patients, offering predictable and immediate durability after implantation," declared Dr. Levi Garraway, Genentech's chief medical officer. Vitreoretinal surgeon Dr. Carl Awh echoed this sentiment: "Susvimo is a compelling new treatment... I am delighted to have this far more durable treatment available for my patients."
The FDA’s decision was fueled by the Phase III Pavilion study, where Susvimo users demonstrated superior improvements in retinal health compared to those under monthly observation requiring injections as needed. Astonishingly, none receiving Susvimo needed supplemental treatment at one year. This breakthrough offers not just preserved vision, but a significant reduction in the treatment burden, liberating patients from the relentless cycle of frequent eye injections6, 7.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.